Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameMicroport Neuro
Stock Code02172
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities神經介入醫療器械行業的中國公司,致力於向醫生及患者提供創新解決方案,產品涵蓋出血性腦卒中、腦動脈粥樣硬化狹窄及急性缺血性腦卒中三大領域。
Listing Date2022-07-15
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)上海市浦東新區芙蓉花路500號19號樓
Business Address (Hong Kong)香港九龍觀塘道348號宏利廣場5樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitemedneurotech.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 24.64 / shares
Offer Price RangeFinal offer price only, no range
Lot Size1,000 shares
Entry ThresholdHK$ 24,640
Par ValueTo be extracted
Offer Period2022-06-29 to 2022-07-08
Global Offering Shares13,700,000 shares
HK Public Offer Shares (Initial)1,370,000 shares (10.0%)
Public Offer Lots (Initial)1,370lots (Pool A685lots,Pool B685lots)
International Placing Shares (Initial)12,330,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO582,658,100 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share65.0%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 337,568,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 1,000 HK$ 24,640
2 lots 2,000 HK$ 49,280
3 lots 3,000 HK$ 73,920
4 lots 4,000 HK$ 98,560
5 lots 5,000 HK$ 123,200
6 lots 6,000 HK$ 147,840
7 lots 7,000 HK$ 172,480
8 lots 8,000 HK$ 197,120
9 lots 9,000 HK$ 221,760
10 lots 10,000 HK$ 246,400
12 lots 12,000 HK$ 295,680
14 lots 14,000 HK$ 344,960
16 lots 16,000 HK$ 394,240
18 lots 18,000 HK$ 443,520
20 lots 20,000 HK$ 492,800
25 lots 25,000 HK$ 616,000
30 lots 30,000 HK$ 739,200
35 lots 35,000 HK$ 862,400
40 lots 40,000 HK$ 985,600
45 lots 45,000 HK$ 1,108,800
50 lots 50,000 HK$ 1,232,000
60 lots 60,000 HK$ 1,478,400
70 lots 70,000 HK$ 1,724,800
80 lots 80,000 HK$ 1,971,200
90 lots 90,000 HK$ 2,217,600
100 lots 100,000 HK$ 2,464,000
100 lots 100,000 HK$ 2,464,000
120 lots 120,000 HK$ 2,956,800
140 lots 140,000 HK$ 3,449,600
160 lots 160,000 HK$ 3,942,400
180 lots 180,000 HK$ 4,435,200
200 lots 200,000 HK$ 4,928,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
250 lots 250,000 HK$ 6,160,000
300 lots 300,000 HK$ 7,392,000
350 lots 350,000 HK$ 8,624,000
400 lots 400,000 HK$ 9,856,000
450 lots 450,000 HK$ 11,088,000
500 lots 500,000 HK$ 12,320,000
685 lots 685,000 HK$ 16,878,400

Stock Connect Inclusion Analysis

Avg Daily HK Mkt Cap HK$ 5.45B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 14,356,695,584
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利约人民币24.2百万元
Period-End Cash BalanceTo be extracted
Listing Expenses~HK$ 59,468,000
Listing Expenses / Funds Raised~17.62%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201920202021
Operating profit 52,41151,39731,903
Share of associates and JVs 7,517
Profit before tax 52,41151,39731,903
Income tax expense 5,4366,1097,733
Profit for the year 46,97545,28624,170
Income Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 24.6
First Day OpenHK$ 24.7
First Day Change-0.16%
First Day Volume3266920.0
First Day Turnover80710300.0
Use of Proceeds
1、約93.4百萬港元(占估計所得款項凈額的30.0%)將用于研發出血性腦卒中、腦動脈粥樣硬化狹窄及急性缺血性腦卒中治療及通路產品; 2、約55.6百萬港元(占估計所得款項凈額的20.0%)將用于出血性腦卒中、腦動脈粥樣硬化狹窄及急性缺血性腦卒中產品商業化; 3、約41.7百萬港元(占估計所得款項凈額的15.0%)將用于擴張制造設施以擴大生產規模; 4、約55.6百萬港元(占所得款項凈額的20.0%)將用于擴大全球影響力; 5、約27.8百萬港元(占估計所得款項凈額的10.0%)將用于通過戰略收購、投資、合作或該等策略的結合以優化產品組合; 6、約13.9百萬港元(占所得款項凈額的5.0%)將用作營運資金及其他一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
J.P. Morgan Securities (Far East) Limited CE AAB026 中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (2)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (4)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 中国国际金融香港证券有限公司 CE AEN894 富途证券国际(香港)有限公司 CE AZT137 Livermore Holdings Limited CE BJN764
Joint Lead Managers (4)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 中国国际金融香港证券有限公司 CE AEN894 富途证券国际(香港)有限公司 CE AZT137 Livermore Holdings Limited CE BJN764

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Harvest International Premium Value (Secondary Market) Fund SPC 146,287,680 HKD — 43.30% — 6 months 2023-01-15
2 新华网股份有限公司 73,131,520 HKD — 21.70% — 6 months 2023-01-15

Directors & Management

PositionChinese nameEnglish Name
Chairman彭博—
Company Secretary許燕珊—
No director data available.

Major Shareholders

Major Shareholders & Holdings緊隨全球發售完成後(假設超額配股權未獲行使),MP Scientific(由微創醫療全資擁有)持股53.35%,中國微創投資管理持股10.39%,Maxwell Maxcare Science Foundation Limited持股10.97%。
About this page

This page shows Microport Neuro (02172) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect